Hormones

The idea

The most common hormonal mistake in this community is treating estrogen as a toxin. It isn't. Estrogen is a normal hormone in men, with real roles in bone maintenance, lipid balance, mood, libido, and joint comfort. Problems come from the balance shifting too far in either direction: too much relative to androgens, or too little after aggressive suppression. Harm reduction here means understanding the system before touching it — and understanding that every tool for moving estrogen has its own costs.

Aromatization, in plain terms

Some androgens convert to estrogen through the enzyme aromatase, which lives largely in fat tissue. More substrate and more fat tissue generally mean more conversion — which is one reason estrogen issues track with body fat and with the specific compounds used, not just with total androgen load. This is strong basic endocrinology. What it does not give you is a formula: conversion rates vary between individuals, and blood levels of a single hormone, read without symptoms and without the rest of the panel, do not diagnose anything on their own.

Two drug classes, two different mechanisms

Aromatase inhibitors (AIs) block the aromatase enzyme, reducing estrogen production across the body. Selective estrogen receptor modulators (SERMs) work differently: they block the estrogen receptor in some tissues (notably breast tissue) while acting like estrogen in others (such as bone). That distinction is the whole point. An AI lowers estrogen everywhere, including where it is useful; a SERM shields one tissue while leaving systemic estrogen largely intact. Confusing the two — or using one where the other's mechanism was needed — is a recurring community error. Both classes are prescription-only, both have side-effect profiles of their own (bone and lipid effects for AIs with sustained suppression; clotting and visual effects are among the known SERM considerations), and neither is a casual add-on. Evidence label: strong for the mechanisms; weaker for their risk-benefit balance specifically as physique ancillaries, where dedicated trials are scarce.

Prolactin, briefly

Prolactin is a separate axis, most relevant with compounds that raise it (notably certain 19-nor derivatives). Elevated prolactin can contribute to sexual side effects and, in some cases, breast tissue changes. Dopamine agonists lower prolactin by stimulating dopamine receptors that inhibit its release — a mechanism borrowed from the treatment of prolactinomas and Parkinson's disease, not something developed for physique use. They carry their own risks, including impulse-control and cardiac-valve concerns with sustained use, which is why prolactin management belongs with a clinician who can weigh whether the elevation is real, persistent, and symptomatic before any drug is discussed.

Gyno warning signs

Gynaecomastia — breast tissue growth in men — typically announces itself gradually: tenderness, sensitivity, or a firm lump behind the nipple, often on one side first. Early attention matters because established glandular tissue does not reliably regress once formed, and because a lump always deserves clinical assessment to rule out other causes. Tenderness alone is not a diagnosis, and panic is not a plan; a clinician visit is the step that distinguishes the two. Other warning signs worth a prompt conversation include persistent sexual dysfunction, marked mood changes, and any breast discharge.

What we don't know

There is no validated "ideal" estrogen level for men using androgens — only population ranges from men not using them, and wide individual variation in symptoms at any given level. The long-term consequences of repeated estrogen suppression cycles are poorly studied. Anyone selling certainty on this topic is selling something else.

Back to Harm Reduction · Related: Labs & monitoring, Mind & mood. Educational content only. Not medical advice.